Drug maker with St. Pete plant makes a $1B buy
April 15, 2019 - Catalent Inc. agreed to buy Paragon Bioservices for $1.2 billion. Catalent (NYSE: CTLT) is a contract drug manufacturer; its St. Petersburg plant is its primary softgel development and manufacturing facility in North America. Paragon Bioservices is a biotech company that manufactures gene therapies for clinical and commercial use.